Meta-analysis of preclinical pharmacogenomic studies to discover robust and translatable biomarkers of drug response
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
Meta-analysis of preclinical pharmacogenomic studies to discover robust and translatable biomarkers of drug response
Petr Smirnov, Sisira Kadambat Nair, Farnoosh Abbas-Aghababazadeh, Nikta Feizi, Ian Smith, Trevor J. Pugh & Benjamin Haibe-Kains , 2022, DOI
Clinical interpretation of whole-genome and whole-transcriptome sequencing for precision oncology
Vaidehi Jobanputra, Kazimierz O. Wrzeszczynski, Reinhard Buttner, Carlos Caldas, Edwin Cuppen, Sean Grimmond, Torsten Haferlach, Charles Mullighan, Anna Schuh & …
Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomas
Wesley S Van De Geer, Youri Hoogstrate, Kaspar Draaisma, Pierre A Robe, Sander Bins, Ron H J Mathijssen, Pim French, …
Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care
Edwin Cuppen, Olivier Elemento, Richard Rosenquist, Svetlana Nikic, Maarten IJzerman, Isabelle Durand Zaleski, Geert Frederix, Lars-Åke Levin, Charles G. Mullighan, …
Lost by Transcription: Fork Failures, Elevated Expression, and Clinical Consequences Related to Deletions in Metastatic Colorectal Cancer
Marcel Smid, Saskia M. Wilting & John W. M. Martens International Journal of Molecular Sciences, 2022, DOI
Validation of HER2 Status in Whole Genome Sequencing Data of Breast Cancers with the Ploidy-Corrected Copy Number Approach
Marzena Wojtaszewska, Rafał Stępień, Alicja Woźna, Maciej Piernik, Pawel Sztromwasser, Maciej Dąbrowski, Michał Gniot, Sławomir Szymański, Maciej Socha, Piotr Kasprzak, …
Cell cycle alterations associate with a redistribution of mutation rates across chromosomal domains in human cancers
Marina Salvadores & Fran Supek , 2022, DOI
Hotspot propensity across mutational processes
Claudia Arnedo-Pac, Ferran Muiños, Abel Gonzalez-Perez & Nuria Lopez-Bigas , 2022, DOI
Genome-wide mapping of somatic mutation rates uncovers drivers of cancer
Maxwell A. Sherman, Adam U. Yaari, Oliver Priebe, Felix Dietlein, Po-Ru Loh & Bonnie Berger Nature Biotechnology, 2022, DOI
Feasibility of whole‐genome sequencing‐based tumor diagnostics in routine pathology practice
Kris G Samsom, Luuk J Schipper, Paul Roepman, Linda Jw Bosch, Ferry Lalezari, Elisabeth G Klompenhouwer, Adrianus J De Langen, …
Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
Peter H. J. Slootbeek, Iris S. H. Kloots, Minke Smits, Inge M. Van Oort, Winald R. Gerritsen, Jack A. Schalken, …
Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma
James T. Topham, Erica S. Tsang, Joanna M. Karasinska, Andrew Metcalfe, Hassan Ali, Steve E. Kalloger, Veronika Csizmok, Laura M. …
Met de complete DNA-test zie je in één keer alle mogelijke doelgerichte kankerbehandelingen. Patiënt en behandelend arts hebben zo alle beschikbare informatie om samen de beslissing over de behandeling te kunnen nemen.